Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
Abstract Nearly 75% of breast cancers are hormone receptor‐positive (HR+) and human epidermal growth factor receptor type 2‐negative (HER2−), making endocrine therapy the mainstay of treatment for HR+ and HER2− combination. Although endocrine therapy, such as therapy with fulvestrant, is widely used...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-05-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.2095 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846166578970755072 |
|---|---|
| author | Junjie Li Zhonghua Wang Zhimin Shao |
| author_facet | Junjie Li Zhonghua Wang Zhimin Shao |
| author_sort | Junjie Li |
| collection | DOAJ |
| description | Abstract Nearly 75% of breast cancers are hormone receptor‐positive (HR+) and human epidermal growth factor receptor type 2‐negative (HER2−), making endocrine therapy the mainstay of treatment for HR+ and HER2− combination. Although endocrine therapy, such as therapy with fulvestrant, is widely used in the clinic, endocrine resistance (primary or secondary) is inevitable and poses a serious clinical concern. However, the therapeutic landscape of HR+/HER2− breast cancer is rapidly changing and evolving. In recent years, molecular insights into the genome of HR+/HER2− breast cancer have helped to identify promising targets, such as alterations in signaling pathways [phosphatidylinositide 3‐kinase (PI3K/AKT/mammalian target of rapamycin (mTOR)], dysregulation of the cell cycle (CDK4/6), and identification of new ESR1 mutations. These insights have led to the development of newer targeted therapies, which aims at significantly improving survival in these patients. This review summarizes the role and rationale of fulvestrant when used as a monotherapy or in combination with targeted therapies in patients with HR+/HER2− advanced breast cancer. We also discuss other novel agents and potential future combination treatment options. |
| format | Article |
| id | doaj-art-0107fdb0692b4b5ca1efce046274f67f |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2019-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-0107fdb0692b4b5ca1efce046274f67f2024-11-15T13:01:04ZengWileyCancer Medicine2045-76342019-05-01851943195710.1002/cam4.2095Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A reviewJunjie Li0Zhonghua Wang1Zhimin Shao2Department of Surgery in Breast Cancer Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Surgery in Breast Cancer Fudan University Shanghai Cancer Center Shanghai ChinaDepartment of Surgery in Breast Cancer Fudan University Shanghai Cancer Center Shanghai ChinaAbstract Nearly 75% of breast cancers are hormone receptor‐positive (HR+) and human epidermal growth factor receptor type 2‐negative (HER2−), making endocrine therapy the mainstay of treatment for HR+ and HER2− combination. Although endocrine therapy, such as therapy with fulvestrant, is widely used in the clinic, endocrine resistance (primary or secondary) is inevitable and poses a serious clinical concern. However, the therapeutic landscape of HR+/HER2− breast cancer is rapidly changing and evolving. In recent years, molecular insights into the genome of HR+/HER2− breast cancer have helped to identify promising targets, such as alterations in signaling pathways [phosphatidylinositide 3‐kinase (PI3K/AKT/mammalian target of rapamycin (mTOR)], dysregulation of the cell cycle (CDK4/6), and identification of new ESR1 mutations. These insights have led to the development of newer targeted therapies, which aims at significantly improving survival in these patients. This review summarizes the role and rationale of fulvestrant when used as a monotherapy or in combination with targeted therapies in patients with HR+/HER2− advanced breast cancer. We also discuss other novel agents and potential future combination treatment options.https://doi.org/10.1002/cam4.2095advanced breast cancerfulvestrantHER2−HR+targeted therapies |
| spellingShingle | Junjie Li Zhonghua Wang Zhimin Shao Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review Cancer Medicine advanced breast cancer fulvestrant HER2− HR+ targeted therapies |
| title | Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review |
| title_full | Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review |
| title_fullStr | Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review |
| title_full_unstemmed | Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review |
| title_short | Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review |
| title_sort | fulvestrant in the treatment of hormone receptor positive human epidermal growth factor receptor 2 negative advanced breast cancer a review |
| topic | advanced breast cancer fulvestrant HER2− HR+ targeted therapies |
| url | https://doi.org/10.1002/cam4.2095 |
| work_keys_str_mv | AT junjieli fulvestrantinthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancerareview AT zhonghuawang fulvestrantinthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancerareview AT zhiminshao fulvestrantinthetreatmentofhormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativeadvancedbreastcancerareview |